AMRNNasdaq

AMARIN CORP PLCUK

Healthcare·Oncology·Commercial·Dublin, Ireland
OncologyNeurologyOphthalmologyCardiovascularInfectious DiseaseMetabolic

AMARIN CORP PLCUK (AMRN): 5 pipeline candidates · 1 upcoming catalyst · ~41 mo cash runway. Updated within the last hour.

8.0/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway10.0

40.7 months

Financial Health9.3

D/E 0.44 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth8.5

5 candidates

Catalyst Momentum2.0

1 upcoming, next in ~2567d

Insider SignalN/A

N/A

A transparent, data-derived signal for AMARIN CORP PLCUKacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$321.2M

Cash

$131.1M

Quarterly Burn

$29.1M

Runway

40.7 mo

Revenue

$45.1M

Cash Runway vs Catalysts

A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.

Cash ends ~Nov 2029
Today~93 mo out
Catalyst within runwayCatalyst after cash runs out

Pipeline (5 candidates)

DrugPhase
ciprofloxacinApproved
vascepaApproved
vascepaApproved
VASCEPA (VAZKEPA in EU)Approved
VASCEPA (VAZKEPA)Approved

Upcoming Catalysts (1)

Patent_ExpiryPatent/Exclusivity Expiry: VASCEPA

Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

63

Total value held

$45.7M

HolderSharesValue
sarissa capital management lp1,673,395$24.2M
millennium management llc300,536$4.3M
morgan stanley293,172$4.2M
waterfront wealth inc.203,338$2.9M
two sigma investments, lp107,542$1.6M
susquehanna international group, llp95,767$1.4M
citadel advisors llc91,575$1.3M
bnp paribas financial markets75,503$1.1M
lcm capital management inc43,462$628K
state street corp24,949$361K

Showing top 10 of 63 institutional holders of AMARIN CORP PLCUK. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Mr. Aaron D. Berg

Frequently asked questions

How many drug candidates are in AMARIN CORP PLCUK's pipeline?

AMARIN CORP PLCUK (AMRN) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is AMARIN CORP PLCUK's lead drug candidate?

AMARIN CORP PLCUK's most advanced tracked candidate is ciprofloxacin (Approved) for INDICATIONS AND USAGE Ciprofloxacin Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens * Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group) * Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this orga.

What is AMARIN CORP PLCUK's next catalyst?

AMARIN CORP PLCUK's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: VASCEPA" — expected June 28, 2033.

What is AMARIN CORP PLCUK's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, AMARIN CORP PLCUK has approximately 40.7 months of cash runway.

What is AMARIN CORP PLCUK's market capitalization?

AMARIN CORP PLCUK's market capitalization is approximately $321.2M.

Get the full picture on AMARIN CORP PLCUK

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar